Decision

Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2021 FCA 128 (Tadalafil*)

Justice Rennie - 2021-06-29

Read full decision. Automatically generated summary:

The respondent Mylan Pharmaceuticals ULC moves for an order precluding the appellants Eli Lilly Canada Inc., Eli Lilly and Company, Lilly Del Caribe, Inc., Lilly, S.A., and ICOS Corporation from referring to UK 1,404,340 Patent (UK patent) in their memorandum of fact and law, including the UK patent in the joint book of authorities or placing the UK patent before the panel hearing the appeal. [see 2021 FCA 127]

Decision relates to:

 

Canadian Intellectual Property